Stock Events

Sarepta Therapeutics 

$150.76
132
-$1.9-1.24% Today

Statistics

Day High
153.26
Day Low
150.38
52W High
155.48
52W Low
55.68
Volume
455
Avg. Volume
424
Mkt Cap
1.23T
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-5.86
-3.63
-1.41
0.82
Expected EPS
-0.02
Actual EPS
0.73

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0L35.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap158.95B
Pfizer is developing gene therapies for Duchenne muscular dystrophy (DMD), directly competing with Sarepta's DMD treatments.
Sangamo Therapeutics
SGMO
Mkt Cap66.92M
Sangamo Therapeutics is working on genomic medicines, including treatments for DMD, which competes with Sarepta's gene therapy portfolio.
Sorrento Therapeutics
SRNE
Mkt Cap0
Sorrento Therapeutics has a diverse pipeline including treatments for diseases that Sarepta also targets, making them competitors in the biotech space.
Biomarin Pharmaceutical
BMRN
Mkt Cap15.47B
BioMarin Pharmaceutical competes with Sarepta in the rare disease space, particularly in treatments for DMD.
PTC Therapeutics
PTCT
Mkt Cap2.37B
PTC Therapeutics offers treatment for DMD, competing directly with Sarepta's DMD therapies.
Solid Biosciences
SLDB
Mkt Cap225.29M
Solid Biosciences is focused on developing therapies for DMD, positioning it as a direct competitor to Sarepta.
Dyadic International DE
DYAI
Mkt Cap42.1M
Dyadic International is working on developing and manufacturing biopharmaceuticals for diseases that Sarepta also targets.
Vertex Pharmaceuticals
VRTX
Mkt Cap122.46B
Vertex Pharmaceuticals is involved in treating cystic fibrosis and other diseases, competing with Sarepta in the broader rare disease market.
Ultragenyx Pharmaceutical
RARE
Mkt Cap3.4B
Ultragenyx Pharmaceutical focuses on rare diseases, including some that overlap with Sarepta's target indications.
Biogen
BIIB
Mkt Cap32.85B
Biogen has a broad portfolio in neurology and rare diseases, competing with Sarepta in areas like gene therapy for neurological disorders.

About

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Douglas S. Ingram Esq.
Employees
1314
Country
US
ISIN
US8036071004
WKN
000A1J1BH

Listings